Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BK-specific CTLs for BK/JC Virus Infections in Malignancies/Immunocompromised
NCT02479698Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2015
- Primary completion
- Jul 2027
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic BK-specific cytotoxic T lymphocytes in BK virus infection, progressive multifocal leukoencephalopathy (PML), sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2015; status: recruiting.
02
Drugs
allogeneic BK-specific cytotoxic T lymphocytes
03
Conditions
BK virus infectionprogressive multifocal leukoencephalopathy (PML)
Beyond the preview
Go deeper on NCT02479698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02479698.